TP53 mutations in MPN
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-07 — Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.: cross-connection with calr-mutations: Acquired TP53 mutations are a dominant driver of adverse LFS/OS specifically within CALR-mutated MPN, independent of the CALR driver itself. (novelty: 3)
- 2026-09-19 — Clinicopathologic Characteristics of SomaticMutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.: PRISMA-guided pooled synthesis quantifies TP53 in Ph-negative MPN: ~3% overall prevalence rising to ~10% in MF and AP/BP, roughly balanced single-hit (52%) vs multi-hit (48%) allelic configurations with mean VAF ~37%, and a phase-stratified survival gradient in which multi-hit status worsens OS specifically in chronic-phase disease. (novelty: 3)